AbbVie reported positive topline results from the Phase 3 CERVINO trial for etentamig. The investigational treatment targets patients with relapsed or refractory multiple myeloma. The study met dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS).
Etentamig, a BCMA x CD3 bispecific T-cell engager, achieved an ORR of 74.0%. Standard therapies produced an ORR of 45.7% in the comparison group. The treatment demonstrated a 60% reduction in the risk of disease progression or death.
The drug showed a manageable safety profile with low rates of severe cytokine release syndrome (CRS). AbbVie plans to discuss these results with global regulatory authorities.